Thomas D Hooghe

No ORCID on file · 3 papers in corpus
observational 2022
Cost-effectiveness analysis of recombinant human follicle-stimulating hormone alfa(r-hFSH) and urinary highly purified menopausal gonadotropin (hMG) based on data from a large German registry
Best practice & research. Clinical obstetrics & gynaecology ·doi:10.1016/j.bpobgyn.2022.02.002

This was a retrospective real-world evidence analysis of the costs per live birth for reference recombinant human follicle-stimulating hormone alfa (r-hFSH-alfa) versus highly purified urinary human menopausal gonadotropin (hMG-HP), based o…

review 2022
Originator recombinant human follitropin alfa versus recombinant human follitropin alfa biosimilars in Spain: A cost-effectiveness analysis of assisted reproductive technology related to fresh embryo transfers
Best practice & research. Clinical obstetrics & gynaecology ·doi:10.1016/j.bpobgyn.2022.01.011

This study compared the cost per live birth and cost-effectiveness of the originator recombinant human follicle-stimulating hormone follitropin alfa (r-hFSH-alfa) and r-hFSH-alfa biosimilars for ovarian stimulation prior to assisted reprodu…

2007
No Difference in Cycle Pregnancy Rate and in Cumulative Live-Birth Rate Between Women With Surgically Treated Minimal to Mild Endometriosis and Women With Unexplained Infertility After Controlled Ovarian Hyperstimulation and Intrauterine Insemination
·doi:10.1097/01.ogx.0000253529.85686.72

Whether and how minimal to mild endometriosis is related to subfertility remains a controversial issue. Retrospective studies have pointed to reduced fecundity in these women compared to those with unexplained infertility. Studies of the ef…